Is There Any Advantage of Using Polyclonal vs. Monoclonal Antibodies for Passive Enhancement of Immunity in Patients with COVID-19? | Zendy

AI Assistant Blog Pricing

Open Access

Is There Any Advantage of Using Polyclonal vs. Monoclonal Antibodies for Passive Enhancement of Immunity in Patients with COVID-19?

Author(s) -

Sohail Rao,

Caitlin White,

Manish Singh

Publication year - 2021

Publication title -

dhr proceedings

Language(s) - English

Resource type - Journals

ISSN - 2689-839X

DOI - 10.47488/dhrp.v1is5.31

Subject(s) - polyclonal antibodies , monoclonal antibody , covid-19 , immunity , virology , monoclonal , antibody , immunology , passive immunity , medicine , immune system , disease , outbreak , infectious disease (medical specialty)

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Download on the

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.